Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Overview

Información sobre este estudio

The purpose of part one of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and safety profile of Q901 monotherapy when administered via intravenous (IV) infusion once-weekly (QW) for 4 weeks and once every 2 weeks (Q2W) thereafter. Also, to establish for future clinical development the recommended Phase 2 dose (RP2D) of Q901 monotherapy when administered via IV infusion QW for 4 weeks and Q2W thereafter. 

The purpose of part two of this study is to evaluate safety and tolerability and evidence of anticancer activity of Q901 as monotherapy and in combination with pembrolizumab. In Part 2 Cohort 1, an expansion phase at the established RP2D will be undertaken in participants with selected advanced solid tumors. In Part 2 Cohort 2, a safety run in and expansion phase will be undertaken with Q901 at the RP2D administered in combination with pembrolizumab (400 mg Q6W) in participants with advanced solid tumors.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Participants with histologically or cytologically confirmed advanced or metastatic
ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or
pancreatic cancer, who have progressed following standard-of-care therapy or for whom
there is no standard therapy that confers clinical benefit

- Measurable disease per RECIST v 1.1

- ECOG performance status 0,1 or 2

- Life expectancy of at least 3 months

- Age ≥ 18 years

- Signed, written IRB-approved informed consent form

Exclusion Criteria:

- New York Heart Association Class III or IV cardiac disease, or myocardial infarction,
severe unstable angina, coronary/peripheral artery bypass graft, congestive heart
failure within the past 6 months

- Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470
msec (females) and >450 msec (males)

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy

- Active, poorly controlled autoimmune or inflammatory diseases

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/26/2024. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Hao Xie, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Hani Babiker, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Mitesh Borad, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20543201

Mayo Clinic Footer